Johnson & Johnson (NYSE:JNJ) Shares Sold by Rhumbline Advisers

Rhumbline Advisers lessened its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,214,532 shares of the company's stock after selling 31,009 shares during the quarter. Johnson & Johnson comprises approximately 0.5% of Rhumbline Advisers' portfolio, making the stock its 22nd biggest position. Rhumbline Advisers owned about 0.18% of Johnson & Johnson worth $609,506,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of JNJ. AMF Tjanstepension AB increased its position in Johnson & Johnson by 14.2% during the 3rd quarter. AMF Tjanstepension AB now owns 425,261 shares of the company's stock worth $68,985,000 after purchasing an additional 52,997 shares during the period. Alpha Financial Partners LLC acquired a new position in Johnson & Johnson during the third quarter worth $209,000. Wealth Group Ltd. acquired a new position in Johnson & Johnson during the third quarter worth $213,000. Swedbank AB lifted its holdings in Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company's stock valued at $358,980,000 after acquiring an additional 111,570 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI boosted its position in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company's stock worth $15,798,000 after purchasing an additional 1,768 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on JNJ shares. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating for the company in a report on Thursday, January 23rd. Argus raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Friday, January 24th. Royal Bank of Canada reissued an "outperform" rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday. Morgan Stanley dropped their price objective on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating for the company in a research note on Thursday, January 23rd. Finally, Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They set an "outperform" rating and a $190.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded up $2.67 during midday trading on Friday, reaching $162.35. 12,540,171 shares of the company were exchanged, compared to its average volume of 9,073,381. The firm's 50-day simple moving average is $148.93 and its 200-day simple moving average is $155.90. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a market capitalization of $390.87 billion, a price-to-earnings ratio of 24.41, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts' consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.29 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.